What is Qiagen's earnings per share (EPS)?

Qiagen (QGEN) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 424.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Qiagen Financials

QGEN

Source SEC Filings (10-K/10-Q) Updated Mar 19, 2026 Currency USD FYE March

This page shows Qiagen (QGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 67/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Qiagen has an operating margin of 22.3%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 72/100, reflecting efficient cost management and pricing power. This is up from 4.9% the prior year.

Growth

Qiagen's revenue grew 5.7% year-over-year to $2.1B, a solid pace of expansion. This earns a growth score of 43/100.

Leverage

Qiagen carries a low D/E ratio of 0.44, meaning only $0.44 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.90, Qiagen holds $3.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.

Cash Flow

Qiagen converts 21.7% of revenue into free cash flow ($453.3M). This strong cash generation earns a score of 79/100.

Returns

Qiagen's ROE of 11.3% shows moderate profitability relative to equity, earning a score of 36/100. This is up from 2.3% the prior year.

Altman Z-Score Safe

3.50

Qiagen scores 3.50, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.5B) relative to total liabilities ($2.5B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Qiagen passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.54x

For every $1 of reported earnings, Qiagen generates $1.54 in operating cash flow ($654.3M OCF vs $424.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

22.3x

Qiagen earns $22.3 in operating income for every $1 of interest expense ($465.9M vs $20.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.1B

YoY+5.7%

5Y CAGR+2.2%

10Y CAGR+5.0%

Qiagen generated $2.1B in revenue in fiscal year 2025. This represents an increase of 5.7% from the prior year.

EBITDA

$659.6M

YoY+119.2%

5Y CAGR+2.2%

10Y CAGR+5.9%

Qiagen's EBITDA was $659.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 119.2% from the prior year.

Net Income

$424.9M

YoY+408.3%

5Y CAGR+3.4%

10Y CAGR+12.6%

Qiagen reported $424.9M in net income in fiscal year 2025. This represents an increase of 408.3% from the prior year.

EPS (Diluted)

$1.94

YoY+424.3%

5Y CAGR+4.9%

10Y CAGR+13.4%

Qiagen earned $1.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 424.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$453.3M

YoY-10.5%

5Y CAGR+6.9%

10Y CAGR+7.5%

Qiagen generated $453.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 10.5% from the prior year.

Cash & Debt

$839.0M

YoY+26.4%

5Y CAGR+7.0%

10Y CAGR+11.2%

Qiagen held $839.0M in cash against $1.7B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.25

Qiagen paid $0.25 per share in dividends in fiscal year 2025.

Shares Outstanding

217M

YoY-2.4%

5Y CAGR-1.0%

10Y CAGR-0.7%

Qiagen had 217M shares outstanding in fiscal year 2025. This represents a decrease of 2.4% from the prior year.

Margins & Returns

Gross Margin

62.2%

YoY+13.3pp

5Y CAGR-3.7pp

10Y CAGR-2.3pp

Qiagen's gross margin was 62.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 13.3 percentage points from the prior year.

Operating Margin

22.3%

YoY+17.3pp

5Y CAGR+1.6pp

10Y CAGR+8.3pp

Qiagen's operating margin was 22.3% in fiscal year 2025, reflecting core business profitability. This is up 17.3 percentage points from the prior year.

Net Margin

20.3%

YoY+16.1pp

5Y CAGR+1.1pp

10Y CAGR+10.2pp

Qiagen's net profit margin was 20.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 16.1 percentage points from the prior year.

Return on Equity

11.3%

YoY+8.9pp

5Y CAGR-1.6pp

10Y CAGR+6.2pp

Qiagen's ROE was 11.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 8.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$187.5M

YoY-3.1%

5Y CAGR+4.7%

10Y CAGR+2.5%

Qiagen invested $187.5M in research and development in fiscal year 2025. This represents a decrease of 3.1% from the prior year.

Share Buybacks

$280.1M

YoY-4.1%

5Y CAGR+34.3%

10Y CAGR+29.7%

Qiagen spent $280.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 4.1% from the prior year.

Capital Expenditures

$201.0M

YoY+20.3%

5Y CAGR+8.6%

10Y CAGR+7.5%

Qiagen invested $201.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.3% from the prior year.

QGEN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.1B+5.7%	$2.0B+0.7%	$2.0B-8.2%	$2.1B-4.9%	$2.3B+20.4%	$1.9B
Cost of Revenue	$790.5M-21.8%	$1.0B+38.2%	$731.6M-3.3%	$757.0M-5.5%	$800.8M+25.6%	$637.6M
Gross Profit	$1.3B+34.3%	$967.4M-21.6%	$1.2B-10.9%	$1.4B-4.6%	$1.5B+17.7%	$1.2B
R&D Expenses	$187.5M-3.1%	$193.5M-2.5%	$198.5M+4.6%	$189.9M-0.1%	$190.0M+27.4%	$149.1M
SG&A Expenses	$125.7M+10.8%	$113.4M-4.9%	$119.3M-8.1%	$129.7M+1.3%	$128.1M+14.7%	$111.7M
Operating Income	$465.9M+376.8%	$97.7M-76.2%	$409.9M-22.9%	$531.5M-15.7%	$630.1M+63.1%	$386.4M
Interest Expense	$20.9M-52.3%	$43.8M-17.9%	$53.4M-8.5%	$58.4M+7.1%	$54.5M-23.6%	$71.3M
Income Tax	$65.4M+74.1%	$37.6M-57.6%	$88.5M-1.0%	$89.4M-21.1%	$113.2M+41.0%	$80.3M
Net Income	$424.9M+408.3%	$83.6M-75.5%	$341.3M-19.4%	$423.2M-17.4%	$512.6M+42.7%	$359.2M
EPS (Diluted)	$1.94+424.3%	$0.37-75.0%	$1.48-19.6%	$1.84-16.7%	$2.21+44.4%	$1.53

Metric	Q3'25	Q3'24	Q3'23	Q3'22	Q3'21	Q3'20	Q3'19	Q3'18
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

QGEN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.3B+10.4%	$5.7B-7.0%	$6.1B-2.7%	$6.3B+2.3%	$6.1B+4.7%	$5.9B
Current Assets	$2.0B+1.8%	$2.0B-8.7%	$2.1B-10.3%	$2.4B+13.5%	$2.1B+29.9%	$1.6B
Cash & Equivalents	$839.0M+26.4%	$663.6M-0.7%	$668.1M-8.6%	$730.7M-17.0%	$880.5M+47.2%	$598.0M
Inventory	$301.9M+8.1%	$279.3M-29.9%	$398.4M+11.3%	$358.0M+9.3%	$327.5M+12.5%	$291.2M
Accounts Receivable	$402.6M+15.3%	$349.3M-8.5%	$381.9M+18.0%	$323.8M-10.6%	$362.1M-4.8%	$380.5M
Goodwill	$2.7B+11.3%	$2.4B-2.0%	$2.5B+5.2%	$2.4B+0.1%	$2.4B-0.6%	$2.4B
Total Liabilities	$2.5B+17.9%	$2.1B-8.0%	$2.3B-18.2%	$2.8B-7.5%	$3.1B-0.7%	$3.1B
Current Liabilities	$512.1M-5.8%	$543.6M-49.6%	$1.1B+10.8%	$974.5M-35.8%	$1.5B+165.2%	$572.2M
Long-Term Debt	$1.7B+23.6%	$1.3B+45.2%	$921.8M-37.4%	$1.5B+34.5%	$1.1B-41.8%	$1.9B
Total Equity	$3.8B+5.9%	$3.6B-6.3%	$3.8B+9.8%	$3.5B+12.0%	$3.1B+10.7%	$2.8B
Retained Earnings	$2.7B+12.3%	$2.4B-0.4%	$2.5B+13.7%	$2.2B+20.6%	$1.8B+35.4%	$1.3B

Metric	Q3'25	Q3'24	Q3'23	Q3'22	Q3'21	Q3'20	Q3'19	Q3'18
Total Assets	$5.7B-7.0%	$6.1B-2.7%	$6.3B+2.3%	$6.1B+4.7%	$5.9B+12.1%	$5.2B-8.9%	$5.7B+14.1%	$5.0B
Current Assets	$2.0B-8.7%	$2.1B-10.3%	$2.4B+13.5%	$2.1B+29.9%	$1.6B+3.4%	$1.6B-27.1%	$2.2B+30.8%	$1.6B
Cash & Equivalents	$663.6M-0.7%	$668.1M-8.6%	$730.7M-17.0%	$880.5M+47.2%	$598.0M-4.1%	$623.6M-46.2%	$1.2B+76.2%	$657.7M
Inventory	$279.3M-29.9%	$398.4M+11.3%	$358.0M+9.3%	$327.5M+12.5%	$291.2M+70.6%	$170.7M+4.8%	$162.9M+4.5%	$155.9M
Accounts Receivable	$349.3M-8.5%	$381.9M+18.0%	$323.8M-10.6%	$362.1M-4.8%	$380.5M-1.2%	$385.1M+9.5%	$351.6M+6.8%	$329.1M
Goodwill	$2.4B-2.0%	$2.5B+5.2%	$2.4B+0.1%	$2.4B-0.6%	$2.4B+10.4%	$2.1B+1.5%	$2.1B+4.8%	$2.0B
Total Liabilities	$2.1B-8.0%	$2.3B-18.2%	$2.8B-7.5%	$3.1B-0.7%	$3.1B+13.8%	$2.7B-13.3%	$3.1B+24.7%	$2.5B
Current Liabilities	$543.6M-49.6%	$1.1B+10.8%	$974.5M-35.8%	$1.5B+165.2%	$572.2M-39.9%	$951.3M-2.1%	$972.2M+199.3%	$324.8M
Long-Term Debt	$1.3B+45.2%	$921.8M-37.4%	$1.5B+34.5%	$1.1B-41.8%	$1.9B+32.3%	$1.4B-15.0%	$1.7B-5.0%	$1.8B
Total Equity	$3.6B-6.3%	$3.8B+9.8%	$3.5B+12.0%	$3.1B+10.7%	$2.8B+10.3%	$2.5B-3.7%	$2.6B+3.7%	$2.5B
Retained Earnings	$2.4B-0.4%	$2.5B+13.7%	$2.2B+20.6%	$1.8B+35.4%	$1.3B+12.3%	$1.2B-14.6%	$1.4B+10.6%	$1.2B

QGEN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$654.3M-2.9%	$673.6M+46.6%	$459.5M-35.8%	$715.3M+11.9%	$639.0M+39.6%	$457.8M
Capital Expenditures	$201.0M+20.3%	$167.2M+11.7%	$149.7M+15.9%	$129.2M-32.0%	$189.9M+43.0%	$132.8M
Free Cash Flow	$453.3M-10.5%	$506.4M+63.5%	$309.7M-47.1%	$586.0M+30.5%	$449.1M+38.2%	$325.0M
Investing Cash Flow	-$305.3M-22.5%	-$249.2M-184.3%	-$87.7M+87.9%	-$726.8M-259.0%	-$202.4M+54.3%	-$443.3M
Financing Cash Flow	-$179.0M+57.7%	-$422.9M+2.5%	-$433.8M-244.8%	-$125.8M+16.3%	-$150.4M-200.0%	-$50.1M
Dividends Paid	$54.2M	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$280.1M-4.1%	$292.1M	$0	$0-100.0%	$100.0M+56.2%	$64.0M

Metric	Q3'25	Q3'24	Q3'23	Q3'22	Q3'21	Q3'20	Q3'19	Q3'18
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

QGEN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.2%+13.3pp	48.9%-13.9pp	62.8%-1.9pp	64.6%+0.2pp	64.4%-1.5pp	65.9%
Operating Margin	22.3%+17.3pp	4.9%-15.9pp	20.9%-4.0pp	24.8%-3.2pp	28.0%+7.3pp	20.7%
Net Margin	20.3%+16.1pp	4.2%-13.1pp	17.4%-2.4pp	19.8%-3.0pp	22.8%+3.6pp	19.2%
Return on Equity	11.3%+8.9pp	2.3%-6.6pp	9.0%-3.3pp	12.2%-4.3pp	16.6%+3.7pp	12.8%
Return on Assets	6.8%+5.3pp	1.5%-4.1pp	5.6%-1.1pp	6.7%-1.6pp	8.3%+2.2pp	6.1%
Current Ratio	3.90+0.3	3.61+1.6	1.99-0.5	2.46+1.1	1.39-1.4	2.84
Debt-to-Equity	0.44+0.1	0.38+0.1	0.24-0.2	0.42+0.1	0.35-0.3	0.67
FCF Margin	21.7%-3.9pp	25.6%+9.8pp	15.8%-11.6pp	27.4%+7.4pp	20.0%+2.6pp	17.4%

Metric	Q3'25	Q3'24	Q3'23	Q3'22	Q3'21	Q3'20	Q3'19	Q3'18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	3.61+1.6	1.99-0.5	2.46+1.1	1.39-1.4	2.84+1.2	1.65-0.6	2.22-2.9	5.07
Debt-to-Equity	0.38+0.1	0.24-0.2	0.42+0.1	0.35-0.3	0.67+0.1	0.56-0.1	0.63-0.1	0.69
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Revvity Inc RVTY

$9.9B

Charles Riv Labs Intl Inc CRL

$8.6B

Guardant Health GH

$12.3B

Radnet RDNT

$4.3B

Sotera Health Co SHC

$4.3B

Frequently Asked Questions

What is Qiagen's annual revenue?

Qiagen (QGEN) reported $2.1B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Qiagen's revenue growing?

Qiagen (QGEN) revenue grew by 5.7% year-over-year, from $2.0B to $2.1B in fiscal year 2025.

Is Qiagen profitable?

Yes, Qiagen (QGEN) reported a net income of $424.9M in fiscal year 2025, with a net profit margin of 20.3%.

What is Qiagen's EBITDA?

Qiagen (QGEN) had EBITDA of $659.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Qiagen have?

As of fiscal year 2025, Qiagen (QGEN) had $839.0M in cash and equivalents against $1.7B in long-term debt.

What is Qiagen's gross margin?

Qiagen (QGEN) had a gross margin of 62.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Qiagen's operating margin?

Qiagen (QGEN) had an operating margin of 22.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Qiagen's net profit margin?

Qiagen (QGEN) had a net profit margin of 20.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Qiagen pay dividends?

Yes, Qiagen (QGEN) paid $0.25 per share in dividends during fiscal year 2025.

What is Qiagen's return on equity (ROE)?

Qiagen (QGEN) has a return on equity of 11.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Qiagen's free cash flow?

Qiagen (QGEN) generated $453.3M in free cash flow during fiscal year 2025. This represents a -10.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Qiagen's operating cash flow?

Qiagen (QGEN) generated $654.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Qiagen's total assets?

Qiagen (QGEN) had $6.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Qiagen's capital expenditures?

Qiagen (QGEN) invested $201.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Qiagen spend on research and development?

Qiagen (QGEN) invested $187.5M in research and development during fiscal year 2025.

Does Qiagen buy back shares?

Yes, Qiagen (QGEN) spent $280.1M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Qiagen have outstanding?

Qiagen (QGEN) had 217M shares outstanding as of fiscal year 2025.

What is Qiagen's current ratio?

Qiagen (QGEN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.

What is Qiagen's debt-to-equity ratio?

Qiagen (QGEN) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Qiagen's return on assets (ROA)?

Qiagen (QGEN) had a return on assets of 6.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Qiagen's Altman Z-Score?

Qiagen (QGEN) has an Altman Z-Score of 3.50, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Qiagen's Piotroski F-Score?

Qiagen (QGEN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Qiagen's earnings high quality?

Qiagen (QGEN) has an earnings quality ratio of 1.54x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Qiagen cover its interest payments?

Qiagen (QGEN) has an interest coverage ratio of 22.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Qiagen?

Qiagen (QGEN) scores 67 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.